Objective:Based on the perspective of Universal Health Coverage(UHC),a mathematical model was developed to conduct quantitative study on the development status of Basic Medical Insurance Schemes(BMIS) in China.Methods:A mixed model was developed to conduct quantitative study on the development of BMIS in the period of 2003-2015 from five dimensions:coverage of population,benefit package,reimbursement rate,risk pooling level and unity of the schemes.Sensitivity analysis was also performed.Results:The UHC scores for BMIS in China from 2003 to 2015 fluctuated obviously.Given the range of 0-100 percent,the UHC score in 2003 was 52.2％,28.5％ in 2006,23.9％ in 2010 and 26.5％ in 2015.The integration and equalization of BMIS and scaling up the risk pooling levels were shown to contribute significantly to UHC.Conclusion:The construction of mixed models was developed to provide a new calculation assessment tool for measuring the UHC,which consisted of completed evaluation tool package with addition model and multiplication model.Considering the future development of UHC,there is a still long way to go for BMIS in China.Emphases should be given to integration and equalization of BMIS as well as scaling up the risk polling to provincial and national level.

Two highly specific monoclonal antibodies with potentul affinity against hepatocellular carcinoma HAb18, HAb25 as carriers, 131I and adriamycin (ADM) as warhead "double bomb"-mixed monoclonal antibodies immunoconjugates(131I-HAb18-ADM)/(131I-HAb25-ADM) was prepared by indirectly conjugated with dextran T-40 and chloramine-T methods. The immunoconjugating rate to target cells was 42.5%, labelling rate 49.8%, and specific radioactivity 6.88?104Bq/?g. In vitro, (131I-HAb18-ADM)/(131I-HAb25-ADM) showed stronger selective cytotoxicity against target tumor cells than either HAb18-ADM, or 131I-HAb18, or HAb25-ADM, or 131I-HAb25 conjugate alone(P